Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Children's Cancer Institute Australia for Medical Research
Recent studies from Australia, the South Korea and Brazil add new data to neurology research
August 18th, 2006
Investigators in Australia, the South Korea and Brazil have published new neurology data. Study 1: Poor neuroblastoma outcome could be due to high-level MRP1 expression, implicating MRP1 as a therapeutic target for reversing chemotherapy resistance. According to a study from Australia, "We have previously shown in a retrospective study that expression of the multidrug transporter gene MRP1 (ABCC1) is associated with outcome in neuroblastoma. We have now undertaken a prospective analysis to examine the independent prognostic significance of MRP1 expression in a large cohort of primary untreated neuroblastomas. Two hundred nine diagnostic neuroblastoma...
Source: Biotech Law Weekly (2006-08-18)
|
